Historical data shows that a consistent $500 monthly investment into Atrium Therapeutics, Inc. (RNA) starting in 2020 would have turned a total investment of $46K into $31K today. This represents a total return of -33.6% over the 6-year period, compounding through dividend reinvestment and market growth.
The Impact of Dividend Reinvestment (DRIP)
Atrium Therapeutics, Inc. does not currently pay a notable dividend. For growth-focused stocks like RNA, dollar cost averaging relies entirely on price appreciation. Over the 6-year period, the strategy successfully captured the stock's price movements, resulting in a final portfolio value of $31K without the need for dividend reinvestment.
RNA vs. S&P 500 (SPY) Benchmark
When comparing this dollar cost averaging strategy against a broad market index,RNA underperformed the S&P 500 ETF (SPY). The same $500 monthly contributions into SPY would have grown to $81K, compared to RNA's $31K.